Close menu




Biotech

Photo credits: pixabay.com

Commented by Nico Popp on October 17th, 2022 | 12:21 CEST

Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?

  • Biotechnology
  • Turnaround

After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.

Read

Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST

Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!

  • Biotechnology
  • Cancer

Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?

Read

Commented by Fabian Lorenz on October 12th, 2022 | 11:33 CEST

TUI share soon to be a penny stock? BASF, BioNTech, Cardiol Therapeutics - buy or sell?

  • Biotechnology
  • chemicals

Buy or sell? It is not only the BASF share that is currently the subject of clearly differing opinions. While the gas price brake plans on Monday caused euphoria among investors and correspondingly rising prices for the shares of the chemical company, analysts from Goldman Sachs and Morgan Stanley continue to express pessimism. Experts are similarly cautious about the prospects for TUI. UBS even sees the share of the tourism group on the way to becoming a penny stock. Analysts are more optimistic about BioNTech, but the share is not making any headway at the moment. In contrast, experts see massive upside potential in the biotech gem Cardiol Therapeutics. Cash is now equal to market capitalization, and drug development is making progress.

Read

Commented by André Will-Laudien on October 12th, 2022 | 11:31 CEST

Biotech in the scope: BioNTech, XPhyto Therapeutics, MorphoSys, Valneva - The cards are reshuffled!

  • Biotechnology
  • Pharma

Cancer remains one of the greatest afflictions of our time, along with cardiovascular disease. Despite the tremendous progress already made in the fight against cancer, there remains an unmet medical need for many types of cancer. Cancer was responsible for nearly 10 million deaths worldwide in 2020. Other diseases, such as Alzheimer's and Parkinson's, also continue to be the focus of research. How is the biotech industry faring after the pandemic and during the stock market storm?

Read

Commented by Stefan Feulner on October 10th, 2022 | 10:43 CEST

BioNTech, Fonterelli GmbH & Co KGaA, Fonterelli SPAC 2 AG, MorphoSys - Bullish forecasts

  • Investments
  • Biotechnology
  • Covid19

The capital-intensive biotech and pharma sector has been stuck in a correction since the central banks changed their strategy at the beginning of the stock market year. In particular, vaccine manufacturers, which have exploded since the outbreak of COVID-19, have lost disproportionately in value since their highs in August of last year. However, the pandemic is likely to be with us for the next few years, albeit in a weakened form. The development of new drugs benefits companies that could now face a similar path as the vaccine producers.

Read

Commented by Stefan Feulner on October 6th, 2022 | 11:43 CEST

Nordex, Cardiol Therapeutics, Rock Tech Lithium - Great opportunities in bombed-out stocks

  • Biotechnology
  • Lithium
  • GreenTech

The market correction of recent months due to geopolitical conflicts, fears of recession, and rising interest rates have taken their toll. While the broad market indices such as the DAX with 23% or the NASDAQ 100 technology index with 30% slipped into the red zone year-to-date, growth and financially intensive stocks, in particular, have suffered losses of over 70% in some cases. Despite corporate successes, the stocks have been sold off and are trading below their cash levels in some cases. In the long term, these are outstanding entry opportunities for patient investors.

Read

Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

  • Biotechnology
  • Pharma
  • Investments
  • Technology

About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

Read

Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

  • Technology
  • Biotechnology
  • Investments

The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

Read

Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

  • Biotechnology

Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

Read

Commented by Juliane Zielonka on September 23rd, 2022 | 11:28 CEST

Defence Therapeutics, Amazon, BioNTech - Innovative technologies for health

  • Biotechnology
  • Investments
  • Healthcare

While WHO Director-General Tedros Adhanom Ghebreyesus sees the end of the Corona pandemic within reach, companies like BioNTech have more products in the pipeline to bring successful drugs to market. In order to ensure that this happens thoroughly and more quickly, Canadian company Defence Therapeutics is stepping up to shorten development cycles with a unique platform technology in oncology. Cancer has still not been eradicated. An end, however, is in sight for Amazon's in-house healthcare division. Amazon Care is closing its doors at the end of the year, but the Seattle-based corporation still cannot let go of the lucrative healthcare business...

Read